Diabetes, obesity and vascular disease - An update

Current Pharmaceutical Design

Volumn 19, Issue 27, 2013, Pages 4900-4903

  Papanas, Nikolaos ^a   Katsiki, Niki ^b   Putz, Zsuzsanna ^c   Mikhailidis, Dimitri P ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ALDOSE REDUCTASE INHIBITOR; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENFOTIAMINE; CAPSAICIN; GABAPENTIN; GHRELIN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIDOCAINE; LIRAGLUTIDE; METFORMIN; NICOTINIC ACID; OPIATE; PHENTERMINE PLUS TOPIRAMATE; PIOGLITAZONE; SALICYLIC ACID; THIAZIDE DIURETIC AGENT; THIOCTIC ACID; TOPIRAMATE; URIC ACID;

ACUPUNCTURE; ADVERSE OUTCOME; AGE; ATHEROSCLEROSIS; BLADDER CANCER; CANCER LOCALIZATION; CANCER RISK; CARDIOVASCULAR RISK; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; ENDOTHELIAL DYSFUNCTION; EXERCISE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERURICEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FAILURE; KIDNEY FUNCTION; METABOLIC SYNDROME X; MICROALBUMINURIA; MORBIDITY; MORTALITY; NEUROPATHIC PAIN; OBESITY; PANCREAS ISLET BETA CELL; PHOTOTHERAPY; PRIORITY JOURNAL; SMOKING; TRANSCUTANEOUS NERVE STIMULATION; URIC ACID BLOOD LEVEL; VASCULAR DISEASE;

BIOMEDICAL RESEARCH; COMBINED MODALITY THERAPY; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; EVIDENCE-BASED MEDICINE; HUMANS; OBESITY;

EID: 84881359005     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319270013     Document Type: Editorial

References (76)

1. Colagiuri S, Borch-Johnsen K, Glümer C, Vistisen D. There really is an epidemic of type 2 diabetes. Diabetologia 2005; 48: 1459-63.
2. Wareham NJ. Epidemiology of type 2 diabetes. Endocrinol Nutr 2009; 56 Suppl 4: 60-2.
3. Howel D. Waist circumference and abdominal obesity among older adults: patterns, prevalence and trends. PLoS One 2012; 7: e48528.
4. Xi B, Liang Y, He T, Reilly KH, Hu Y, Wang Q et al. Secular trends in the prevalence of general and abdominal obesity among Chinese adults, 1993-2009. Obes Rev 2012; 13: 287-96.
5. Paraskevas KI, Bessias N, Papas TT, Gekas CD, Andrikopoulos V, Mikhailidis DP. Do different vascular risk factors affect all arteries equally? Angiology 2008; 59: 397-401.
6. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-96.
7. Papanas N, Maltezos E. Antidiabetic treatment: Though lovers be lost, love shall not. World J Diabetes 2012; 3: 158-60.
8. Banach M, Malodobra-Mazur M, Gluba A, Katsiki N, Rysz J, Dobrzyn A. Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr Pharm Des 2013; 19(27): 4904-12.
9. Lewis SJ. Lipid-lowering therapy: who can benefit? Vasc Health Risk Manag 2011; 7: 525-34.
10. Mikhailidis DP, Elisaf M, Rizzo M, Berneis K, Griffin B, Zambon A et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011; 9: 531-2.
11. Koh KK, Quon MJ, Sakuma I, Han SH, Choi H, Lee K et al. Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients. Int J Cardiol 2011 Dec 26. [Epub ahead of print].
12. Koh KK, Quon MJ, Sakuma I, Lee Y, Lim S, Han SH et al. Effects of simvastatin therapy on circulating adipocytokines in patients with hypercholesterolemia. Int J Cardiol 2011; 146: 434-7.
13. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305: 2556-64.
14. Kostapanos MS, Elisaf MS, Mikhailidis DP. Pioglitazone and cancer: angel or demon? Curr Pharm Des 2013; 19(27): 4913-29.
15. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916-22.
16. Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011; 34: 1369-71.
17. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012; 35: 278-80.
18. Dormandy JA, Charbonnel B, Eckland DJ Erdmann E, Massi-Benedetti M, Moules IK et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89.
19. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674-85.
20. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006; 17: 328-36.
21. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011; 306: 737-45.
22. Papanas N, Maltezos E, Mikhailidis DP. Metformin and cancer: licence to heal? Expert Opin Investig Drugs 2010; 19: 913-7.
23. Katsiki N, Papanas N, Fonseca VA, Maltezos E, Mikhailidis DP. Uric acid and diabetes: is there a link? Curr Pharm Des 2012; current issue, in press
24. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006; 55: 1293-301.
25. Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis DP. Uric acid levels and vascular disease. Curr Med Res Opin 2004; 20: 951-4.
26. Modan M, Halkin H, Karasik A, Lusky A. Elevated serum uric acid-a facet of hyperinsulinaemia. Diabetologia 1987; 30: 713-8.
27. Chou P, Lin KC, Lin HY, Tsai ST. Gender differences in the relationships of serum uric acid with fasting serum insulin and plasma glucose in patients without diabetes. J Rheumatol 2001; 28: 571-6.
28. Papanas N, Katsiki N, Papatheodorou K, Demetriou M, Papazoglou D, Gioka T et al. Peripheral neuropathy is associated with increased serum levels of uric acid in type 2 diabetes mellitus. Angiology 2011; 62: 291-5.
29. Papanas N, Demetriou M, Katsiki N, Papatheodorou K, Papazoglou D, Gioka T et al. Increased serum levels of uric acid are associated with sudomotor dysfunction in subjects with type 2 diabetes mellitus. Exp Diabetes Res 2011; 2011: 346051.
30. Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes 2009; 58: 1668-71.
31. Jalal DI, Rivard CJ, Johnson RJ, Maahs DM, McFann K, Rewers M et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dial Transplant 2010; 25: 1865-9.
32. Cai XL, Wang F, Ji LN. Risk factors of diabetic retinopathy in type 2 diabetic patients. Chin Med J (Engl) 2006; 119: 822-6.
33. Fukui M, Tanaka M, Shiraishi E, Harusato I, Hosoda H, Asano M et al. Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus. Metabolism 2008; 57: 625-9.
34. Rathmann W, Hauner H, Dannehl K, Gries FA. Association of elevated serum uric acid with coronary heart disease in diabetes mellitus. Diabete Metab 1993; 19: 159-66.
35. Seghieri G, Moruzzo D, Fascetti S, Bambini C, Anichini R, De Bellis A et al. Increase in serum uric acid is selectively associated with stroke in type 2 diabetes. Diabetes Care 2002; 25: 1095.
36. Newman EJ, Rahman FS, Lees KR, Weir CJ, Walters MR. Elevated serum urate concentration independently predicts poor outcome following stroke in patients with diabetes. Diabetes Metab Res Rev 2006; 22: 79-82.
37. Gouni-Berthold I, Brüning JC, Berthold HK. Novel approaches to the pharmacotherapy of obesity. Curr Pharm Des 2013; 19(27): 4938-52.
38. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11: 722-33.
39. Greenway FL, Dunayevich E, Tollefson G, Erickson J, Guttadauria M, Fujioka K et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 2009; 94: 4898-906.
40. Astrup A, Rossner S, Van GL, Rissanen A, Niskanen L, Al HM et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-16.
41. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36: 843-54.
42. Rizzo M, Rizvi AA, Sudar E, Soskic S, Obradovic M, Montalto G et al. A review of the cardiovascular and anti-atherogenic effects of ghrelin. Curr Pharm Des 2013; 19(27): 4953-63.
43. Kellokoski E, Kunnari A, Jokela M, Mäkelä S, Kesäniemi YA, Hörkkö S. Ghrelin and obestatin modulate early atherogenic processes on cells: enhancement of monocyte adhesion and oxidized low-density lipoprotein binding. Metabolism 2009; 58: 1572-80.
44. Vestergaard ET, Gormsen LC, Jessen N, Lund S, Hansen TK, Moller N et al. Ghrelin infusion in humans induces acute insulin resistance and lipolysis independent of growth hormone signaling. Diabetes 2008; 57: 3205-10.
45. Dezaki K, Sone H, Koizumi M, Nakata M, Kakei M, Nagai H et al. Blockade of pancreatic islet-derived ghrelin enhances insulin secretion to prevent high-fat diet-induced glucose intolerance. Diabetes 2006; 55: 3486-93.
46. Lioudaki E, Florentin M, Ganotakis ES, Mikhailidis DP. Microalbuminuria: a neglected cardiovascular risk factor in non-diabetic individuals? Curr Pharm Des 2013; 19(27): 4964-80.
47. Jorgensen L, Jenssen T, Johnsen SH, Mathiesen EB, Heuch I, Joakimsen O et al. Albuminuria as risk factor for initiation and progression of carotid atherosclerosis in non-diabetic persons: the Tromso Study. Eur Heart J 2007; 28: 363-9.
48. Athyros VG, Kakafika AI, Karagiannis A, Mikhailidis DP. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis 2008; 200: 1-12.
49. Karagiannis A, Mikhailidis DP, Tziomalos K, Kakafika AI, Athyros VG. Has the time come for a new definition of microalbuminuria? Curr Vasc Pharmacol 2008; 6: 81-3.
50. Várkonyi T, Putz Z, Keresztes K, Martos T, Lengyel C, Stirban A et al. Advances in the treatment of diabetic neuropathy. Curr Pharm Des 2013; 19(27): 4981-5007.
51. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 2012; 6: CD007543.
52. Papanas N, Maltezos E. α-Lipoic acid, diabetic neuropathy, and Nathan's prophecy. Angiology 2012; 63: 81-3.
53. Papanas N, Maltezos E, Edmonds M. Salvation of the diabetic foot: still a quest for the Holy Grail? Vasa 2011; 40: 267-9.
54. Edmonds M. Modern treatment of infection and ischaemia to reduce major amputation in the diabetic foot. Curr Pharm Des 2013; 19(27): 5008-15.
55. Georgakarakos E, Papanas N, Papadaki E, Georgiadis GS, Maltezos E, Lazarides MK. Endovascular treatment of critical ischemia in the diabetic foot: new thresholds, new anatomies. Angiology 2012 Nov 4. [Epub ahead of print].
56. Antonoglou C, Papanas N, Maltezos E. Lipid-lowering therapy in the diabetic foot: seeing the whole iceberg and not just the tip. Curr Vasc Pharmacol 2012 Sep 24. [Epub ahead of print].
57. Tiaka EK, Papanas N, Manolakis AC, Maltezos E. The role of hyperbaric oxygen in the treatment of diabetic foot ulcers. Angiology 2012; 63: 302-14.
58. Papanas N, Eleftheriadou I, Tentolouris N, Maltezos E. Advances in the topical treatment of diabetic foot ulcers. Curr Diabetes Rev 2012; 8: 209-18.
59. Grove EL, Gregersen S. Antiplatelet therapy in patients with diabetes mellitus. Curr Vasc Pharmacol 2012; 10: 494-505.
60. Vazzana N, Ranalli P, Cuccurullo C, Davì G. Diabetes mellitus and thrombosis. Thromb Res 2012; 129: 371-7.
61. Di Minno MN, Lupoli R, Palmieri NM, Russolillo A, Buonauro A, Di Minno G. Aspirin resistance, platelet turnover, and diabetic angiopathy: a 2011 update. Thromb Res 2012; 129: 341-4.
62. Jagroop IA, Mikhailidis DP. Platelets and diabetes: a complex association. Platelets 2012; in press.
63. Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006; 7: 211-28.
64. Defina LF, Vega GL, Leonard D, Grundy SM. Fasting glucose, obesity, and metabolic syndrome as predictors of type 2 diabetes: the Cooper Center longitudinal study. J Investig Med 2012 Oct 29. [Epub ahead of print].
65. Bergman M. Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine 2012 Nov 7. [Epub ahead of print].
66. Goldberg RB, Mather K. Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program. Arterioscler Thromb Vasc Biol 2012; 32: 2077-90.
67. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet 2012; 379: 2279-90.
68. Papanas N, Vinik AI, Ziegler D. Neuropathy in prediabetes: does the clock start ticking early? Nat Rev Endocrinol 2011; 7: 682-90.
69. Wendland EM, Torloni MR, Falavigna M, Trujillo J, Dode MA, Campos MA et al. Gestational diabetes and pregnancy outcomes--a systematic review of the World Health Organization (WHO) and the International Association of Diabetes in Pregnancy Study Groups (IADPSG) diagnostic criteria. BMC Pregnancy Childbirth 2012; 12: 23.
70. Wang S, Park JK, Duh EJ. Novel targets against retinal angiogenesis in diabetic retinopathy. Curr Diab Rep 2012; 12: 355-63.
71. Kumar B, Gupta SK, Saxena R, Srivastava S. Current trends in the pharmacotherapy of diabetic retinopathy. J Postgrad Med 2012; 58: 132-9.
72. Peto T, Tadros C. Screening for diabetic retinopathy and diabetic macular edema in the United Kingdom. Curr Diab Rep 2012; 12: 338-45.
73. Dhanireddy KK. Pancreas transplantation. Gastroenterol Clin North Am 2012; 41: 133-42.
74. Koshizaka M, Green JB, Alexander JH. Glycemic management in diabetes and the associated cardiovascular risk: are we helping or hurting our patients? Circ J 2012; 76: 1572-80.
75. Inkster B, Zammitt NN, Frier BM. Drug-induced hypoglycaemia in type 2 diabetes. Expert Opin Drug Saf 2012; 11: 597-614.
76. Katsiki N, Papanas N, Mikhailidis DP. Dapagliflozin: more than just another oral glucose-lowering agent? Expert Opin Investig Drugs 2010; 19: 1581-9.